A potential breakthrough drug, referred to as Compound X, has demonstrated significant improvements in mobility and balance for mice exhibiting Parkinson’s-like symptoms. This innovative treatment enhances the brain’s waste-processing capabilities, effectively removing toxic protein aggregates. However, the research team has yet to disclose the specifics of this compound.

“With intellectual property considerations, we recognize that Compound X represents a pivotal advancement, potentially serving as the first disease-modifying intervention for Parkinson’s disease,” stated Zhao Yan from Swinburne University of Technology, Melbourne.

Parkinson’s disease affects over 10 million people globally, characterized by the progressive loss of nerve cells involved in movement control. This degeneration is widely believed to originate from the build-up of misfolded proteins called α-synuclein, due to a malfunction in the brain’s waste disposal system—the glymphatic system. Recent studies aimed to determine if enhancing this system could alleviate symptoms.

To explore this hypothesis, Yang and her colleagues employed a novel mouse model mimicking Parkinson’s disease. This model utilizes repeated nasal administration of misfolded alpha-synuclein, promoting its spread throughout the brain and causing severe motor deficits—more accurately reflecting human Parkinson’s disease compared to traditional models that rely on toxin exposure. Yang showcased her findings at the Oxford Glymphatic and Brain Clearance Symposium in the UK on April 1st.

The team administered weekly doses of alpha-synuclein to 20 mice over four months. After two months, they introduced Compound X—an FDA-approved drug administered four times a week in synergy with methylcellulose, which enhances drug solubility. Preliminary studies indicated that Compound X could increase slow brain waves, known to support glymphatic function, although its specific impact on brain waste clearance warranted further investigation, Yang noted.

The remaining group of mice received only methylcellulose as a control. The progression of Parkinson’s symptoms paralleled early-stage human patients, including alterations in smell and sleep patterns, according to Yang.

Subsequently, all mice underwent a locomotion test involving navigation on a slender rod. Remarkably, 80% of the mice treated with Compound X successfully completed the task, compared to only 10% in the control group.

In another assessment requiring balance on a rotating rod for five minutes, nearly all Compound X-treated mice maintained their position throughout the duration, while the control group averaged just three minutes.

Further analyses revealed that Compound X enhanced slow-wave activity during deep sleep and facilitated fluid circulation within the glymphatic system. Notably, this treatment reduced α-synuclein aggregates in the mice’s motor cortex by approximately 40% compared to the control group.

“This discovery holds significant potential,” emphasized Duan Wenzhen from Johns Hopkins University, Maryland. “The medical community requires treatments that can decelerate disease progression. Current therapies only alleviate symptoms temporarily, lacking efficacy in altering the disease’s trajectory.”

The research team aspires to obtain regulatory approval for human trials targeting early-stage Parkinson’s patients within the upcoming year. “Our ultimate goal is to provide treatment that addresses the early stages of the disease, where the most significant benefits are realized,” Yang concluded.